CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.

ABSTRACT: The Reverse Chimeric Antigen Receptor (RevCAR) system is an adapter CAR T cell technology that allows the precise tuning of T cell activity and, thus, improved safety management. RevCAR T cells recognize and eradicate tumor cells via a bispecific adapter molecule, termed the RevCAR Target Module (RevTM). To further reduce the risk of on-target off-tumor toxicities, Dual-RevCAR T cells can be employed. These cells harbor two different RevCAR constructs, with the signaling domain of either CD3zeta or CD28. Therefore, Dual-RevCAR T cells only exert their full function when both RevCAR constructs are triggered simultaneously upon recognition of two different tumor antigens via RevTMs, enabling a precise AND-gate targeting approach and rendering them highly interesting for clinical application.

SUBMITTER: von Jutrzenka-Trzebiatowski A 

PROVIDER: S-EPMC12154027 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature